• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种优化的 SpCas9 高保真变体,用于直接蛋白递送。

An optimized SpCas9 high-fidelity variant for direct protein delivery.

机构信息

Department CIBIO, Laboratory of Molecular Virology, University of Trento, Via Sommarive 9, 38123 Trento, Italy.

Imagine Institute, Laboratory of Chromatin and Gene Regulation During Development, Université de Paris, INSERM UMR 1163, Paris, France.

出版信息

Mol Ther. 2023 Jul 5;31(7):2257-2265. doi: 10.1016/j.ymthe.2023.03.007. Epub 2023 Mar 10.

DOI:10.1016/j.ymthe.2023.03.007
PMID:36905119
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10362380/
Abstract

Electroporation of the Cas9 ribonucleoprotein (RNP) complex offers the advantage of preventing off-target cleavages and potential immune responses produced by long-term expression of the nuclease. Nevertheless, the majority of engineered high-fidelity Streptococcus pyogenes Cas9 (SpCas9) variants are less active than the wild-type enzyme and are not compatible with RNP delivery. Building on our previous studies on evoCas9, we developed a high-fidelity SpCas9 variant suitable for RNP delivery. The editing efficacy and precision of the recombinant high-fidelity Cas9 (rCas9HF), characterized by the K526D substitution, was compared with the R691A mutant (HiFi Cas9), which is currently the only available high-fidelity Cas9 that can be used as an RNP. The comparative analysis was extended to gene substitution experiments where the two high fidelities were used in combination with a DNA donor template, generating different ratios of non-homologous end joining (NHEJ) versus homology-directed repair (HDR) for precise editing. The analyses revealed a heterogeneous efficacy and precision indicating different targeting capabilities between the two variants throughout the genome. The development of rCas9HF, characterized by an editing profile diverse from the currently used HiFi Cas9 in RNP electroporation, increases the genome editing solutions for the highest precision and efficient applications.

摘要

电穿孔 Cas9 核糖核蛋白(RNP)复合物具有防止脱靶切割和由核酸酶长期表达产生的潜在免疫反应的优势。然而,大多数工程化的高保真链球菌 Cas9(SpCas9)变体的活性低于野生型酶,并且与 RNP 递送不兼容。基于我们之前对 evoCas9 的研究,我们开发了一种适合 RNP 递送的高保真 SpCas9 变体。通过 K526D 取代的重组高保真 Cas9(rCas9HF)的编辑效率和精度与目前唯一可用的可作为 RNP 使用的高保真 Cas9(HiFi Cas9)的 R691A 突变体进行了比较。比较分析扩展到基因替代实验,其中两种高保真度与 DNA 供体模板结合使用,针对精确编辑产生不同比例的非同源末端连接(NHEJ)与同源定向修复(HDR)。分析表明,两种变体在整个基因组中具有不同的靶向能力,表现出不均匀的效率和精度。rCas9HF 的开发具有与当前在 RNP 电穿孔中使用的 HiFi Cas9 不同的编辑特征,为最高精度和高效应用增加了基因组编辑解决方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bee/10362380/3634b2ab9dba/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bee/10362380/10c67d2696b9/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bee/10362380/d6826d637e06/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bee/10362380/9b282a328ad2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bee/10362380/28504f0790cb/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bee/10362380/3634b2ab9dba/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bee/10362380/10c67d2696b9/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bee/10362380/d6826d637e06/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bee/10362380/9b282a328ad2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bee/10362380/28504f0790cb/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bee/10362380/3634b2ab9dba/gr4.jpg

相似文献

1
An optimized SpCas9 high-fidelity variant for direct protein delivery.一种优化的 SpCas9 高保真变体,用于直接蛋白递送。
Mol Ther. 2023 Jul 5;31(7):2257-2265. doi: 10.1016/j.ymthe.2023.03.007. Epub 2023 Mar 10.
2
Superior Fidelity and Distinct Editing Outcomes of SaCas9 Compared with SpCas9 in Genome Editing.SaCas9 与 SpCas9 在基因组编辑中的高保真度和明显的编辑效果比较。
Genomics Proteomics Bioinformatics. 2023 Dec;21(6):1206-1220. doi: 10.1016/j.gpb.2022.12.003. Epub 2022 Dec 20.
3
Developing Heritable Mutations in Arabidopsis thaliana Using a Modified CRISPR/Cas9 Toolkit Comprising PAM-Altered Cas9 Variants and gRNAs.使用包含 PAM 改变的 Cas9 变体和 gRNA 的改良 CRISPR/Cas9 工具包在拟南芥中开发可遗传突变。
Plant Cell Physiol. 2019 Oct 1;60(10):2255-2262. doi: 10.1093/pcp/pcz118.
4
CRISPR-Cas ribonucleoprotein mediated homology-directed repair for efficient targeted genome editing in microalgae IMET1.CRISPR-Cas核糖核蛋白介导的同源定向修复用于微藻IMET1中的高效靶向基因组编辑
Biotechnol Biofuels. 2019 Mar 25;12:66. doi: 10.1186/s13068-019-1401-3. eCollection 2019.
5
A highly specific SpCas9 variant is identified by in vivo screening in yeast.在酵母体内筛选出一种高度特异性的 SpCas9 变体。
Nat Biotechnol. 2018 Mar;36(3):265-271. doi: 10.1038/nbt.4066. Epub 2018 Jan 29.
6
In-depth assessment of the PAM compatibility and editing activities of Cas9 variants.深入评估 Cas9 变体的 PAM 兼容性和编辑活性。
Nucleic Acids Res. 2021 Sep 7;49(15):8785-8795. doi: 10.1093/nar/gkab507.
7
Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease.进化的 Cas9 核酸酶的 PAM 扩展和保真度增强的分子基础。
PLoS Biol. 2019 Oct 11;17(10):e3000496. doi: 10.1371/journal.pbio.3000496. eCollection 2019 Oct.
8
Lentiviral Capsid-Mediated Cas9 Ribonucleoprotein Delivery for Efficient and Safe Multiplex Genome Editing.慢病毒衣壳介导的 Cas9 核糖核蛋白递送来实现高效和安全的多重基因组编辑。
CRISPR J. 2021 Dec;4(6):914-928. doi: 10.1089/crispr.2020.0106. Epub 2021 Mar 16.
9
An Efficient Expression and Purification Protocol for SpCas9 Nuclease and Evaluation of Different Delivery Methods of Ribonucleoprotein.SpCas9 核酸酶的高效表达和纯化方案以及核糖核蛋白不同递送方法的评估
Int J Mol Sci. 2024 Jan 28;25(3):1622. doi: 10.3390/ijms25031622.
10
Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.脂质纳米颗粒介导的 CRISPR-Cas9 RNP 与 mRNA/sgRNA 递送至体内外基因编辑的比较分析。
Eur J Pharm Biopharm. 2024 Mar;196:114207. doi: 10.1016/j.ejpb.2024.114207. Epub 2024 Feb 6.

引用本文的文献

1
Quantifying Protein-Nucleic Acid Interactions for Engineering Useful CRISPR-Cas9 Genome-Editing Variants.量化蛋白-核酸相互作用,以工程化有用的 CRISPR-Cas9 基因组编辑变体。
Methods Mol Biol. 2025;2870:227-243. doi: 10.1007/978-1-0716-4213-9_12.
2
Development of artificial transcription factors and their applications in cell reprograming, genetic screen, and disease treatment.人工转录因子的开发及其在细胞重编程、基因筛选和疾病治疗中的应用。
Mol Ther. 2024 Dec 4;32(12):4208-4234. doi: 10.1016/j.ymthe.2024.10.029. Epub 2024 Oct 28.
3
Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 cell therapy to induce fetal hemoglobin for sickle cell disease.

本文引用的文献

1
Automated identification of sequence-tailored Cas9 proteins using massive metagenomic data.利用海量宏基因组数据自动识别序列定制的 Cas9 蛋白。
Nat Commun. 2022 Oct 29;13(1):6474. doi: 10.1038/s41467-022-34213-9.
2
Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease.β-珠蛋白基因校正在人类造血干细胞中的发展作为镰状细胞病的一种潜在持久治疗方法。
Sci Transl Med. 2021 Jun 16;13(598). doi: 10.1126/scitranslmed.abf2444.
3
CRISPR/Cas9 ribonucleoprotein-mediated knockin generation in hTERT-RPE1 cells.
新型 Cas9 基因编辑自体 CD34 细胞疗法诱导镰状细胞病胎儿血红蛋白的开发和 IND 支持研究。
Mol Ther. 2024 Oct 2;32(10):3433-3452. doi: 10.1016/j.ymthe.2024.07.022. Epub 2024 Jul 31.
4
Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responses.CRISPR-Cas9治疗镰状细胞病的安全性和有效性研究突出了疾病特异性反应。
Mol Ther. 2024 Dec 4;32(12):4337-4352. doi: 10.1016/j.ymthe.2024.07.015. Epub 2024 Jul 22.
5
Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cells.碱基编辑技术可在人类类器官和气道上皮细胞中对导致囊性纤维化的 CFTR 突变进行功能校正。
Cell Rep Med. 2024 May 21;5(5):101544. doi: 10.1016/j.xcrm.2024.101544. Epub 2024 May 1.
6
Engineering Cas9: next generation of genomic editors.工程化 Cas9:新一代基因组编辑工具。
Appl Microbiol Biotechnol. 2024 Feb 14;108(1):209. doi: 10.1007/s00253-024-13056-y.
7
Challenges of CRISPR/Cas-Based Cell Therapy for Type 1 Diabetes: How Not to Engineer a "Trojan Horse".基于 CRISPR/Cas 的 1 型糖尿病细胞治疗的挑战:如何不制造“特洛伊木马”。
Int J Mol Sci. 2023 Dec 10;24(24):17320. doi: 10.3390/ijms242417320.
8
Genome editing for sickle cell disease: still time to correct?镰状细胞病的基因组编辑:还有时间进行纠正吗?
Front Pediatr. 2023 Nov 2;11:1249275. doi: 10.3389/fped.2023.1249275. eCollection 2023.
9
Unlocking the secrets of ABEs: the molecular mechanism behind their specificity.揭示 ABEs 的奥秘:特异性背后的分子机制。
Biochem Soc Trans. 2023 Aug 31;51(4):1635-1646. doi: 10.1042/BST20221508.
10
Enrichment strategies to enhance genome editing.基因编辑的富集策略。
J Biomed Sci. 2023 Jul 1;30(1):51. doi: 10.1186/s12929-023-00943-1.
CRISPR/Cas9 核糖核蛋白介导的 hTERT-RPE1 细胞基因敲入。
STAR Protoc. 2021 Mar 24;2(2):100407. doi: 10.1016/j.xpro.2021.100407. eCollection 2021 Jun 18.
4
Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.通过在人造血干细胞中编辑α-珠蛋白基因座对β-地中海贫血的校正。
Blood Adv. 2021 Mar 9;5(5):1137-1153. doi: 10.1182/bloodadvances.2020001996.
5
Genome Editing for β-Hemoglobinopathies: Advances and Challenges.用于β-地中海贫血的基因组编辑:进展与挑战
J Clin Med. 2021 Jan 28;10(3):482. doi: 10.3390/jcm10030482.
6
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.CRISPR-Cas9 基因编辑治疗镰状细胞病和 β-地中海贫血。
N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.
7
Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype.编辑 γ-珠蛋白抑制因子结合位点可恢复胎儿血红蛋白合成并纠正镰状细胞病表型。
Sci Adv. 2020 Feb 12;6(7). doi: 10.1126/sciadv.aay9392. Print 2020 Feb.
8
Directed Evolution of CRISPR/Cas Systems for Precise Gene Editing.CRISPR/Cas 系统的定向进化用于精确的基因编辑。
Trends Biotechnol. 2021 Mar;39(3):262-273. doi: 10.1016/j.tibtech.2020.07.005. Epub 2020 Aug 19.
9
Prediction of the sequence-specific cleavage activity of Cas9 variants.Cas9 变体序列特异性切割活性的预测。
Nat Biotechnol. 2020 Nov;38(11):1328-1336. doi: 10.1038/s41587-020-0537-9. Epub 2020 Jun 8.
10
Gene Therapy for Cystic Fibrosis: Progress and Challenges of Genome Editing.囊性纤维化的基因治疗:基因组编辑的进展与挑战。
Int J Mol Sci. 2020 May 30;21(11):3903. doi: 10.3390/ijms21113903.